ACAmanda E. Calvert

Amanda E. Calvert

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Amanda E. Calvert has a total of 117 co-authors. Here are the top co-authors by number of shared publications:

  • Christin H. Goodman

    Affiliation Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America

    6 shared publications
  • Kerri L. Miazgowicz

    Affiliation Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, Colorado, United States of America

    5 shared publications
  • Carol D. Blair

    Center for Vector-Borne Infectious Diseases, Department of Microbiology, Immunology and Pathology, Colorado State University, Fort Collins, CO 80523, USA

    4 shared publications
  • John T. Roehrig

    Division of Vector-Borne Diseases, Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA

    4 shared publications
  • Aaron C. Brault

    Arboviral Diseases Branch, Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention, Fort Collins, CO 80521, USA

    3 shared publications
  • Brad J. Biggerstaff

    Division of Vector-Borne Diseases, U.S. Centers for Disease Control and Prevention , Fort Collins, Colorado, USA

    3 shared publications

Latest Publications

  • Establishing Potosi Virus as a Human Pathogen

    by Justin R. Abbatemarco, Feroza Begum, Julian A. Villalba, Emily Davis, Julu Bhatnagar, Aaron C. Brault, Amanda E. Calvert, Anthony Chomyk, Carolyn V. Gould, Carlos M. Isada, et al.

  • Open Access

    An engineered anti-Oropouche virus human-murine chimeric immunoglobulin M is a viable substitute for positive human serum controls in diagnostic serology assays

    by Kerri L. Miazgowicz, Christin H. Goodman, Amanda E. Calvert

    Oropouche virus (OROV) is an arbovirus of concern due to its recent geographical expansion and association with teratogenic outcomes. Serodiagnosis of OROV infection relies on methods such as the immunoglobulin M antibody-capture enzyme-linked immunosorbent assay (MAC-ELISA) and the plaque reduction neutralization test (PRNT). For re-emerging viruses such as OROV, sourcing large quantities of sera from acutely infected human donors for use as positive-control assay material is a significant challenge and hinders diagnostic capacity. To overcome this, we engineered and produced OROV119-chIgM, a human-murine chimeric IgM (chIgM) that expresses the variable regions of the murine monoclonal antibody OROV119, reactive to the Gc protein of OROV, on a human IgM backbone. OROV119-chIgM was evaluated in PRNT and MAC-ELISA to determine its suitability as a positive control in each assay. In PRNT, OROV119-chIgM achieved neutralization equivalent to an OROV polyclonal mouse hyperimmune ascitic fluid (MHIAF). Further, OROV119-chIgM exhibited superior performance compared with OROV-positive human donor sera in a MAC-ELISA. Overall, OROV119-chIgM is an attractive alternative to human donor sera assay control material because of its long-term sustainability and consistent batch-to-batch potency. OROV119-chIgM enhances diagnostic capacity by ensuring laboratories are poised to respond rapidly to future OROV outbreaks.

  • Open Access

    Chimeric Vesicular Stomatitis Virus Bearing Western Equine Encephalitis Virus Envelope Proteins E2-E1 Is a Suitable Surrogate for Western Equine Encephalitis Virus in a Plaque Reduction Neutralization Test

    by Kerri L. Miazgowicz, Bailey E. Maloney, Melinda A. Brindley, Mattie Cassaday, Raegan J. Petch, Paul Bates, Aaron C. Brault, Amanda E. Calvert

    In December 2023, infections of western equine encephalitis virus (WEEV) within Argentina were reported to the World Health Organization (WHO). By April 2024, more than 250 human infections, 12 of which were fatal, and 2500 equine infections were identified in South America. Laboratory diagnosis and surveillance in affected countries were hindered by a lack of facilities equipped with BSL-3 laboratories, as confirmatory serodiagnosis for WEEV requires live virus in the plaque reduction neutralization test (PRNT). To expand serodiagnosis for WEEV in the Americas, we developed a virus chimera composed of vesicular stomatitis virus (VSV) engineered to display the E2-E1 glycoproteins of WEEV (VSV/WEEV) in place of the VSV glycoprotein (G). PRNT90 and IC90 values of parental WEEV and VSV/WEEV were analogous using sera collected from mice, horses, and chickens. VSV/WEEV rapidly formed plaques with clear borders and reduced the assay readout time by approximately 8 h compared to the parental virus. Overall, we demonstrate that chimeric VSV/WEEV is a suitable surrogate for WEEV in a diagnostic PRNT. Use of chimeric VSV/WEEV in place of authentic WEEV will dramatically expand testing capacity by enabling PRNTs to be performed at BSL-2 containment, while simultaneously decreasing the health risk to testing personnel.


  • Open Access

    A Scoping Review of Preclinical Research on Monoclonal Antibody Development for Prophylaxis and Treatment of West Nile Virus Infections

    by Amanda E. Calvert, Kerri L. Miazgowicz, Bailey Atkinson, Audrey H. Long, Elisa Thrasher, Aaron C. Brault, Randall J. Nett

    West Nile virus (WNV) causes thousands of arboviral infections in the United States each year. Patients with immune-compromising conditions and elderly people are at higher risk of severe WNV neuroinvasive disease (WNND). Despite its broad endemicity nationwide, no U.S. Food and Drug Administration-approved vaccine or therapeutic treatments exist. We summarized existing peer-reviewed literature on the preclinical development of monoclonal antibody (MAb) prophylaxis and therapeutics for the prevention and treatment of WNND. Five bibliographical databases (CINAHL, Cochrane Library, Embase, MEDLINE, and Scopus) were searched for applicable research studies performed from 1 January 1998 to 1 May 2025. In total, 2347 titles and abstracts were screened, 263 full-text publications reviewed, and 25 studies included. Studies included detailed preclinical development and evaluations of MAbs targeting the envelope (E) protein (n = 13), other viral proteins (n = 3), flaviviral cross-protective monoclonal antibodies (n = 4), and novel antibody configurations or delivery methods (n = 5). The most well-studied MAb, E16, targeting E- Domain III (E-DIII), was effective at inhibiting and treating WNND in experimental animal models. No work investigated ways to traffic therapeutic antibodies across the blood–brain barrier. This review summarizes the current research in the development of monoclonal antibody therapeutics for WNV and addresses gaps in the knowledge for future consideration.


  • Jamestown Canyon Virus Seroprevalence in Endemic Regions and Implications for Diagnostic Testing

    by Rebekah A Sutter, Amanda E Calvert, Kacie Grimm, Brad J Biggerstaff, Elisa Thrasher, Eric C Mossel, Stacey W Martin, Jennifer Lehman, Paula Saa, Rebecca Townsend, et al.

    Background: Jamestown Canyon virus, a mosquito-borne virus, can cause asymptomatic infection, febrile illness, or neuroinvasive disease in humans. Previous studies have found Jamestown Canyon virus–specific antibodies in a 4%–54% of people in various U.S. regions. To understand baseline seroprevalence in regions with the highest number of reported disease cases, we performed a serosurvey among blood donors. Methods: We randomly selected blood donation specimens collected during December 2019–April 2020 from residents of counties reporting ≥2 disease cases in 2019 or 1 case in 2019 and ≥1 case during 2010–2018. Specimens were screened for Jamestown Canyon virus–specific neutralizing antibodies and, if positive, tested for immunoglobulin M (IgM) antibodies. We estimated county population seroprevalence by calibrating sample weights to population census data. Results: Fourteen counties in 3 states, Massachusetts, Minnesota, and Wisconsin, met the inclusion criteria. Within each state, average county seroprevalence ranged from 16.8% (95% confidence interval [CI], 9.3–27.0) to 18.8% (95% CI, 14.0–24.4) for Jamestown Canyon virus–neutralizing antibodies and from 7.6% (95% CI, 4.2–12.5) to 13.5% (95% CI, 9.6–18.3) for both neutralizing and IgM antibodies. Conclusions: Estimated Jamestown Canyon virus seroprevalence, including for IgM antibodies, is elevated in endemic areas, complicating the interpretation of serologic testing in diagnosing acute disease in symptomatic individuals. Diagnosing Jamestown Canyon virus disease requires a high degree of clinical suspicion, ruling out other possible causes of illness, and if possible, collecting acute and convalescent samples. New assays to detect acute infection could improve diagnosis and public health surveillance for Jamestown Canyon virus disease.


  • Open Access

    Development of a Diagnostic IgM Antibody Capture ELISA for Detection of Anti-Cache Valley Virus Human IgM

    by Christin Goodman, Jordan A. Powers, Sierra R. Mikula, Holly R. Hughes, Brad J. Biggerstaff, Kelly Fitzpatrick, Amanda J. Panella, Carlos Machain-Williams, SeungHwan Lee, Amanda E. Calvert

    : Cache Valley virus (CVV), a mosquito-borne orthobunyavirus, causes epizootics in ruminants characterized by congenital malformations and fetal death in North America. Only seven human infections have been identified; limited information exists on its potential as a human teratogen. Diagnosis of CVV infections relies on the plaque reduction neutralization test (PRNT), which requires live virus, is time-consuming, and cannot differentiate between recent and past infections. To improve diagnostics for CVV, we developed an IgM antibody capture ELISA (MAC-ELISA) for detection of anti-CVV human IgM in diagnostic specimens that can be performed faster than PRNT and is specific to IgM, which is essential to determine the timing of infection. Conjointly, a cell line constitutively expressing human-murine chimeric antibody with the variable regions of monoclonal antibody CVV-17 and constant regions of human IgM was developed to provide positive control material. The new cell line produced antibody with reactivity in the assay equivalent to that of a human serum sample positive for anti-CVV IgM. Five of seven archived human specimens diagnostically confirmed as CVV positive tested positive in the MAC-ELISA, whereas 44 specimens confirmed positive for another arboviral infection tested negative, showing good initial correlation of the CVV MAC-ELISA. Two of 27 previously collected serum samples from febrile patients in Yucatán, Mexico, who tested negative for a recent flaviviral or alphaviral infection were positive in both the MAC-ELISA and PRNT, indicating a possible recent infection with CVV or related orthobunyavirus. The MAC-ELISA described here will aid in making diagnostics more widely available for CVV in public health laboratories.


  • Open Access

    Cache Valley virus: an emerging arbovirus of public and veterinary health importance

    by Holly R Hughes, Joan L Kenney, Amanda E Calvert

    Cache Valley virus (CVV) is a mosquito-borne virus in the genus Orthobunyavirus (Bunyavirales: Peribunyaviridae) that has been identified as a teratogen in ruminants causing fetal death and severe malformations during epizootics in the U.S. CVV has recently emerged as a viral pathogen causing severe disease in humans. Despite its emergence as a public health and agricultural concern, CVV has yet to be significantly studied by the scientific community. Limited information exists on CVV’s geographic distribution, ecological cycle, seroprevalence in humans and animals, and spectrum of disease, including its potential as a human teratogen. Here, we present what is known of CVV’s virology, ecology, and clinical disease in ruminants and humans. We discuss the current diagnostic techniques available and highlight gaps in our current knowledge and considerations for future research.


  • Characterization of a monoclonal antibody specific to California serogroup orthobunyaviruses and development as a chimeric immunoglobulin M-positive control in human diagnostics

    by Jordan A. Powers, Karen L. Boroughs, Sierra Mikula, Christin H. Goodman, Emily H. Davis, Elisa M. Thrasher, Holly R. Hughes, Brad J. Biggerstaff, Amanda E. Calvert

    California serogroup viruses (CSGVs) of medical importance in the United States include La Crosse virus, Jamestown Canyon virus (JCV), California encephalitis virus, and snowshoe hare virus. Current diagnosis of CSGVs relies heavily on serologic techniques for detecting immunoglobulin M (IgM), an indication of a recent CSGV infection. However, human-positive control sera reactive to viruses in the serogroup are scarce because detection of recent infections is rare. Here, we describe the development of new murine monoclonal antibodies (MAbs) reactive to CSGVs and the engineering of a human-murine chimeric antibody by combining the variable regions of the broadly CSGV cross-reactive murine MAb, 3-3B6/2-3B2 and the constant region of the human IgM. MAb 3-3B6/2-3B2 recognizes a tertiary epitope on the Gn/Gc heterodimer, and epitopes important in JCV neutralization were mapped to the Gc glycoprotein. This engineered human IgM constitutively expressed in a HEK-293 stable cell line can replace human-positive control sera in diagnostic serological techniques such as IgM antibody capture enzyme-linked immunosorbent assay (MAC-ELISA). Compared to the parent murine MAbs, the human-chimeric IgM antibody had identical serological activity to CSGVs in ELISA and demonstrated equivalent reactivity compared to human immune sera in the MAC-ELISA. Importance: Orthobunyaviruses in the California serogroup cause severe neurological disease in children and adults. While these viruses are known to circulate widely in North America, their occurrence is rare. Serological testing for CSGVs is hindered by the limited availability and volumes of human-positive specimens needed as controls in serologic assays. Here, we described the development of a murine monoclonal antibody cross-reactive to CSGVs engineered to contain the variable regions of the murine antibody on the backbone of human IgM. The chimeric IgM produced from the stably expressing HEK293 cell line was evaluated for use as a surrogate human-positive control in a serologic diagnostic test.


  • Development of HEK-293 Cell Lines Constitutively Expressing Flaviviral Antigens for Use in Diagnostics

    by Jordan A. Powers, Benjamin Skinner, Brent S. Davis, Brad J. Biggerstaff, Lucy Robb, Elizabeth Gordon, William M. de Souza, Marcilio Jorge Fumagalli, Amanda E. Calvert, Gwong-Jen Chang

    Serological diagnostic testing for flaviviral infections is hindered by the need for specialized biocontainment for preparation of reagents and assay implementation. The use of previously developed COS-1 cell lines secreting noninfectious recombinant viral antigen is limited due to diminished antigen secretion over time.


  • Open Access

    Monoclonal antibodies to Cache Valley virus for serological diagnosis

    by Benjamin Skinner, Sierra Mikula, Brent S. Davis, Jordan A. Powers, Holly R. Hughes, Amanda E. Calvert

    Cache Valley virus (CVV) is a mosquito-borne virus in the genusOrthobunyavirus, familyPeribunyaviridae. It was first isolated from aCuliseta inoratamosquito in Cache Valley, Utah in 1956 and is known to circulate widely in the Americas. While only a handful of human cases have been reported since its discovery, it is the causative agent of fetal death and severe malformations in livestock. CVV has recently emerged as a potential viral pathogen causing severe disease in humans. Currently, the only serological assay available for diagnostic testing is plaque reduction neutralization test which takes several days to perform and requires biocontainment. To expand diagnostic capacity to detect CVV infections by immunoassays, 12 hybridoma clones secreting anti-CVV murine monoclonal antibodies (MAbs) were developed. All MAbs developed were found to be non-neutralizing and specific to the nucleoprotein of CVV. Cross-reactivity experiments with related orthobunyaviruses revealed several of the MAbs reacted with Tensaw, Fort Sherman, Tlacotalpan, Maguari, Playas, and Potosi viruses. Our data shows that MAbs CVV14, CVV15, CVV17, and CVV18 have high specific reactivity as a detector in an IgM antibody capture test with human sera.